Department of Defense PTSD Adaptive Platform Trial - Intervention D - SLS-002
Status:
NOT_YET_RECRUITING
Trial end date:
2026-09-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2 randomized, double-blinded, placebo-controlled study that will evaluate multiple potential pharmacotherapeutic interventions for Post Traumatic Stress Disorder (PTSD) utilizing an adaptive platform trial (APT) design.
Intervention D - SLS-002 will assess the safety and efficacy of SLS-002 in participants with PTSD.
Please see NCT05422612 for information on the S-21-02 Master Protocol.
Phase:
PHASE2
Details
Lead Sponsor:
Global Coalition for Adaptive Research
Collaborators:
Berry Consultants Cambridge Cognition Ltd Citeline Idorsia Pharmaceuticals Ltd. PPD Development, LP U.S. Army Medical Research and Development Command